[
  {
    "question": "A 26-year-old female with AIDS (CD4 count: 47) presents to the emergency department in severe pain. She states that over the past week she has been fatigued and has had a progressively worse headache and fever. These symptoms have failed to remit leading her to seek care in the ED. A lumbar puncture is performed which demonstrates an opening pressure of 285 mm H2O, increased lymphocytes, elevated protein, and decreased glucose. The emergency physician subsequently initiates treatment with IV amphotericin B and PO flucytosine. What additional treatment in the acute setting may be warranted in this patient?",
    "answer": "Based on the patient's presentation and laboratory results, it is likely that she has cryptococcal meningitis, a common opportunistic infection in patients with advanced HIV/AIDS. The symptoms of headache, fever, and fatigue, along with the cerebrospinal fluid (CSF) findings of increased opening pressure, elevated lymphocytes, elevated protein, and decreased glucose, are consistent with this diagnosis.\n\nThe treatment initiated by the emergency physician, IV amphotericin B and PO flucytosine, is appropriate for cryptococcal meningitis.\n\nIn the acute setting, an additional treatment that may be warranted is the administration of acetazolamide or other measures to manage increased intracranial pressure (ICP). The patient's elevated opening pressure on lumbar puncture (>250 mm H2O) suggests increased ICP, which can be a complication of cryptococcal meningitis. Acetazolamide, a carbonic anhydrase inhibitor, can help reduce ICP by decreasing CSF production.\n\nOther measures to manage increased ICP may include:\n\n* Frequent lumbar punctures to remove CSF and reduce pressure\n* Corticosteroids (e.g., dexamethasone) to reduce inflammation\n* Head elevation to 30-40 degrees to promote venous drainage\n* Close monitoring of neurological status and vital signs\n\nIt is essential to note that the management of increased ICP should be individualized and guided by a specialist, such as an infectious disease expert or a neurologist.",
    "true_answer": "In the acute setting, serial lumbar punctures may be warranted for this patient to manage elevated intracranial pressure."
  },
  {
    "question": "You are reviewing raw data from a research study performed at your medical center examining the effectiveness of a novel AIDS screening examination. The study enrolled 250 patients with confirmed AIDS, and 240 of these patients demonstrated a positive screening examination. The control arm of the study enrolled 250 patients who do not have AIDS, and only 5 of these patients tested positive on the novel screening examination. What is the NPV of this novel test?",
    "answer": "To calculate the Negative Predictive Value (NPV) of the novel AIDS screening examination, we first need to understand what NPV is. The NPV is the probability that subjects with a negative screening test truly don't have the disease. It is calculated as the number of true negatives (TN) divided by the sum of true negatives and false negatives (FN).\n\nFrom the information provided:\n- True positives (TP) = 240 (patients with AIDS who tested positive)\n- False positives (FP) = 5 (patients without AIDS who tested positive)\n- Total patients with AIDS = 250\n- Total patients without AIDS = 250\n\nTo find the NPV, we need to calculate the number of true negatives and false negatives.\n\nTrue negatives (TN) are the patients without AIDS who tested negative. Since 5 patients without AIDS tested positive, the remaining patients without AIDS tested negative:\nTN = Total patients without AIDS - FP = 250 - 5 = 245\n\nFalse negatives (FN) are the patients with AIDS who tested negative. Since 240 patients with AIDS tested positive, the remaining patients with AIDS tested negative:\nFN = Total patients with AIDS - TP = 250 - 240 = 10\n\nNow, we can calculate the NPV:\nNPV = TN / (TN + FN) = 245 / (245 + 10) = 245 / 255\n\nNPV = 245 / 255 \u2248 0.9608 or 96.08%\n\nTherefore, the Negative Predictive Value of this novel AIDS screening examination is approximately 96.08%. This means that about 96.08% of the patients who test negative on this screening examination truly do not have AIDS.",
    "true_answer": "The NPV of this test is calculated as the proportion of true negatives among all negative results, 245 / (245 + 10) = 0.96."
  },
  {
    "question": "A 46-year-old Caucasian male with past medical history of HIV (CD4: 77/mm^3), hypertension, hyperlipidemia, and osteoarthritis presents to the emergency department with sudden weakness of his right hand. He reports that the weakness has gradually been getting worse and that this morning he dropped his cup of coffee. He has never had anything like this happen to him before, although he was hospitalized last year for pneumonia. He reports inconsistent adherence to his home medications, which include raltegravir, tenofovir, emtricitabine, TMP-SMX, hydrochlorothiazide, pravastatin, and occasional ibuprofen. His father died of a myocardial infarction at the age of 60, and his mother suffered a stroke at the age of 72. The patient's temperature is 102.6\u00b0F (39.2\u00b0C), blood pressure is 156/92 mmHg, pulse is 88/min, and respirations are 18/min. On neurological exam, he has 3/5 strength in the distal muscles of the right extremity with preserved sensation. His neurological exam is normal in all other extremities. What is the next best step in management for this patient?",
    "answer": "The patient presents with sudden weakness of his right hand, which has been gradually worsening, and a history of HIV with a low CD4 count, indicating a compromised immune system. The patient's temperature is elevated at 102.6\u00b0F (39.2\u00b0C), suggesting an infectious or inflammatory process. Given the acute onset of focal neurological deficits (weakness in the distal muscles of the right extremity with preserved sensation), the primary concern is a central nervous system (CNS) infection, stroke, or another acute neurological condition.\n\nThe next best step in management for this patient involves several urgent actions:\n\n1. **Immediate Neuroimaging**: Given the acute onset of focal neurological deficits, an urgent CT scan of the head or an MRI (if available and the patient is stable enough) should be performed to rule out stroke (ischemic or hemorrhagic), CNS infections (such as toxoplasmosis, which is common in HIV patients with low CD4 counts), or other space-occupying lesions.\n\n2. **Laboratory Tests**: \n   - Complete Blood Count (CBC) to assess for signs of infection or inflammation.\n   - Blood cultures to evaluate for bacteremia.\n   - Electrolyte panel and renal function tests to assess for any electrolyte imbalances or renal dysfunction that could contribute to neurological symptoms.\n   - HIV viral load and CD4 count (though the CD4 count is already known, it's essential to monitor) to assess the current status of HIV infection.\n   - Consider testing for syphilis (RPR or VDRL) as neurosyphilis can present with a wide range of neurological symptoms.\n\n3. **Infectious Disease Consultation**: Given the patient's immunocompromised state, consultation with an infectious disease specialist is crucial to guide the management of potential opportunistic infections.\n\n4. **Neurology Consultation**: A neurologist should be involved to interpret the neuroimaging and to guide further management based on the findings.\n\n5. **Supportive Care**: Ensure the patient is hydrated, and manage fever and pain as necessary. Consider starting empiric antibiotics if there is suspicion of a bacterial infection, pending culture results.\n\n6. **Adherence to Antiretroviral Therapy (ART)**: It's crucial to address the patient's inconsistent adherence to his HIV medications. Poor adherence can lead to increased viral replication, further immune suppression, and increased risk of opportunistic infections.\n\n7. **Stroke Protocol**: If the neuroimaging suggests an ischemic stroke, the patient should be evaluated for potential thrombolytic therapy if the time window allows and there are no contraindications.\n\nThe management of this patient requires a multidisciplinary approach, involving emergency medicine, infectious disease, neurology, and potentially other specialties, to address the acute neurological presentation, the underlying HIV infection, and other comorbid conditions.",
    "true_answer": "The next best step in management is to perform a head CT (Computed Tomography) scan to investigate the cause of neurological symptoms."
  },
  {
    "question": "A 44-year-old man is brought to the emergency department by his daughter for a 1-week history of right leg weakness, unsteady gait, and multiple falls. During the past 6 months, he has become more forgetful and has sometimes lost his way along familiar routes. He has been having difficulties operating simple kitchen appliances such as the dishwasher and the coffee maker. He has recently become increasingly paranoid, agitated, and restless. He has HIV, hypertension, and type 2 diabetes mellitus. His last visit to a physician was more than 2 years ago, and he has been noncompliant with his medications. His temperature is 37.2 \u00b0C (99.0 \u00b0F), blood pressure is 152/68 mm Hg, pulse is 98/min, and respirations are 14/min. He is somnolent and slightly confused. He is oriented to person, but not place or time. There is mild lymphadenopathy in the cervical, axillary, and inguinal areas. Neurological examination shows right lower extremity weakness with normal tone and no other focal deficits. Laboratory studies show: Hemoglobin 9.2 g/dL, Leukocyte count 3600/mm3, Platelet count 140,000/mm3, CD4+ count 56/\u03bcL, HIV viral load > 100,000 copies/mL, Serum: Cryptococcal antigen negative, Toxoplasma gondii IgG positive. An MRI of the brain shows disseminated, nonenhancing white matter lesions with no mass effect. What is the most likely diagnosis?",
    "answer": "Based on the clinical presentation and laboratory findings, the most likely diagnosis is Progressive Multifocal Leukoencephalopathy (PML).\n\nHere's why:\n\n1. **Clinical presentation**: The patient has a 1-week history of right leg weakness, unsteady gait, and multiple falls, which suggests a neurological disorder. He also has a 6-month history of cognitive decline, including forgetfulness, difficulty with spatial orientation, and difficulty with operating simple appliances, which suggests a progressive neurological disorder.\n2. **HIV status**: The patient has HIV with a low CD4+ count (56/\u03bcL) and a high viral load (> 100,000 copies/mL), which indicates advanced immunosuppression.\n3. **Neurological examination**: The patient has right lower extremity weakness with normal tone and no other focal deficits, which suggests a lesion in the central nervous system (CNS).\n4. **Laboratory studies**: The patient has a low hemoglobin level, leukopenia, and thrombocytopenia, which are common findings in patients with advanced HIV disease. The negative cryptococcal antigen and positive Toxoplasma gondii IgG are not specific for PML, but they help to rule out other opportunistic infections.\n5. **MRI findings**: The MRI shows disseminated, nonenhancing white matter lesions with no mass effect, which is consistent with PML. PML is a demyelinating disease caused by the JC virus, which affects the white matter of the brain.\n\nPML is a rare and often fatal disease that occurs in individuals with impaired immune systems, such as those with advanced HIV disease. The disease is characterized by progressive damage to the white matter of the brain, leading to cognitive decline, motor weakness, and other neurological symptoms.\n\nOther possible diagnoses, such as toxoplasmosis or CNS lymphoma, are less likely given the clinical presentation and laboratory findings. Toxoplasmosis typically presents with mass lesions and enhancement on MRI, whereas CNS lymphoma often presents with a single mass lesion and more pronounced neurological deficits.\n\nOverall, the combination of advanced HIV disease, progressive neurological symptoms, and characteristic MRI findings makes PML the most likely diagnosis in this case.",
    "true_answer": "The most likely diagnosis is progressive multifocal leukoencephalopathy."
  },
  {
    "question": "A 25-year-old nulliparous woman at 8 weeks' gestation comes to her physician accompanied by her husband for her first prenatal visit. She has no personal or family history of serious illness. Her vaccinations are up-to-date and she takes no medications. She has no history of recreational drug use and does not drink alcohol. Her vital signs are within normal limits. She is 167 cm (5 ft 6 in) tall and weighs 68 kg (150 lb); BMI is 24.3 kg/m2. She tested negative for HIV, Chlamydia trachomatis, and Neisseria gonorrhoeae 4 years ago. What following tests should be done at this visit?",
    "answer": "At the first prenatal visit, several tests and screenings are recommended to ensure the health and well-being of both the mother and the fetus. Given the patient's history and presentation, the following tests should be considered at this visit:\n\n1. **Complete Blood Count (CBC):** To check for anemia and other blood abnormalities.\n2. **Blood Type and Rh Factor:** Determining the blood type (A, B, AB, or O) and Rh factor (positive or negative) is crucial. If the mother is Rh-negative and the father is Rh-positive, there's a risk of Rh incompatibility, which can affect future pregnancies.\n3. **Rubella Immunity:** Confirming immunity to rubella (German measles) is important to prevent congenital rubella syndrome.\n4. **Varicella Immunity:** Testing for immunity to varicella (chickenpox) to assess the risk of varicella infection during pregnancy.\n5. **Hepatitis B Surface Antigen (HBsAg):** Screening for hepatitis B infection, as it can be transmitted to the newborn.\n6. **Syphilis Screening:** Even though she tested negative 4 years ago, syphilis screening is recommended for all pregnant women at the first prenatal visit due to its potential severe consequences for the fetus if left untreated.\n7. **Urine Culture:** To screen for asymptomatic bacteriuria, which can lead to urinary tract infections and potentially affect the pregnancy.\n8. **Pap Smear (if due):** If the patient's last Pap smear was not within the recommended screening interval, it might be performed at this visit, though current guidelines often recommend against routine Pap smears during pregnancy unless abnormalities were previously detected.\n9. **Ultrasound:** An early ultrasound can confirm the gestational age, check for multiple pregnancies, and evaluate for any obvious fetal anomalies.\n10. **HIV Screening:** Repeat HIV screening is recommended for all pregnant women at the initial prenatal visit, regardless of previous test results, due to the potential for new exposures.\n11. **Chlamydia and Gonorrhea Screening:** These sexually transmitted infections can have serious consequences for the fetus and newborn, so screening is recommended, especially if the patient's previous test was more than a year ago or if there have been new sexual partners.\n12. **Group B Streptococcus (GBS) Screening:** Typically performed between 36 and 37 weeks of gestation, but initial prenatal visits often set the stage for understanding the need for this future test.\n\nAdditionally, the first prenatal visit is an opportunity for the healthcare provider to discuss pregnancy nutrition, fetal movement, prenatal vitamins (especially folic acid to prevent neural tube defects), signs of preterm labor, and any concerns or questions the patient or her partner may have. It's also a time to assess for any risk factors that may require more specialized prenatal care.",
    "true_answer": "Tests to conduct at this visit include ELISA for HIV, a rapid plasma reagin test, and serum HBsAg."
  },
  {
    "question": "A 33-year-old HIV-positive male is seen in clinic for follow-up care. When asked if he has been adhering to his HIV medications, the patient exclaims that he has been depressed, thus causing him to not take his medication for six months. His CD4+ count is now 33 cells/mm3. What medication(s) should he take in addition to his anti-retroviral therapy?",
    "answer": "Given the patient's history of depression and non-adherence to his HIV medications, it's essential to address both his mental health and the increased risk of opportunistic infections due to his low CD4+ count. \n\nIn addition to resuming his anti-retroviral therapy (ART), the patient should be considered for prophylactic medications to prevent opportunistic infections, given his CD4+ count is below 200 cells/mm^3. The specific prophylactic medications recommended may depend on various factors including the patient's overall health, other medications he is taking, and local resistance patterns, but common considerations include:\n\n1. **Trimethoprim/Sulfamethoxazole (TMP/SMX)** for the prevention of Pneumocystis jirovecii pneumonia (PCP). This is typically recommended for patients with a CD4+ count below 200 cells/mm^3.\n\n2. **Isoniazid (INH)** for the prevention of tuberculosis (TB), especially if the patient has a positive tuberculin skin test or interferon-gamma release assay and no evidence of active TB.\n\n3. **Fluconazole** for the prevention of cryptococcal disease, particularly if the CD4+ count is below 100 cells/mm^3, although guidelines may vary.\n\n4. **Valganciclovir** or other anti-cytomegalovirus (CMV) medications might be considered in certain cases, especially if there's a high risk of CMV disease, though this is less common as primary prophylaxis.\n\nFor his depression, the patient should be evaluated and treated by a mental health professional. Selective serotonin reuptake inhibitors (SSRIs) are commonly used to treat depression in HIV-positive patients, but the choice of antidepressant should be made considering potential drug interactions with his ART regimen.\n\nIt's crucial for the patient to be closely monitored for adherence to both his ART and any newly initiated prophylactic medications, as well as for signs of depression and other mental health issues. A multidisciplinary approach involving HIV specialists, mental health professionals, and social workers may be beneficial in managing his care comprehensively.",
    "true_answer": "In addition to his antiretroviral therapy, the patient should take azithromycin and trimethoprim-sulfamethoxazole to prevent opportunistic infections."
  },
  {
    "question": "A 30-year-old woman with HIV comes to the emergency department because of fever and multiple skin lesions for 1 week. She also has nausea, anorexia, and abdominal pain. The skin lesions are non-pruritic and painless. She has smoked one pack of cigarettes daily for 15 years and drinks 2 beers daily. She has been using intravenous crack cocaine for 6 years. She appears ill. Her temperature is 38\u00b0C (100.4\u00b0F), pulse is 105/min, blood pressure is 110/75 mm Hg. Her BMI is 19 kg/m2. Examination shows track marks on both cubital fossae. There are white patches on her palate that can be scraped off. There are several red papules measuring 1 to 2 cm on her face and trunk. Her CD4+T-lymphocyte count is 98/mm3 (N \u2265 500). Biopsy of a skin lesion shows vascular proliferation and small black bacteria on Warthin-Starry stain. What is the most appropriate pharmacotherapy?",
    "answer": "Based on the clinical presentation and laboratory findings, the most likely diagnosis is Bacillary Angiomatosis (BA) caused by Bartonella henselae or Bartonella quintana. The characteristic features of BA include:\n\n* Skin lesions with vascular proliferation and presence of small black bacteria on Warthin-Starry stain\n* Immunocompromised state (HIV with low CD4+ T-lymphocyte count)\n* Systemic symptoms such as fever, nausea, anorexia, and abdominal pain\n\nThe most appropriate pharmacotherapy for Bacillary Angiomatosis is:\n\n* Erythromycin: 500 mg orally four times a day for at least 3 months\n* Alternatively, doxycycline: 100 mg orally twice a day for at least 3 months\n* Azithromycin: 500 mg orally on day 1, then 250 mg orally daily for at least 3 months, can also be considered\n\nIt is essential to note that the treatment should be continued for at least 3 months to prevent relapse. Additionally, the patient's HIV status and CD4+ T-lymphocyte count should be monitored, and antiretroviral therapy (ART) should be initiated or optimized as needed.\n\nIn this case, the patient's history of intravenous drug use and smoking also increases her risk for other infections and health complications, and she should be screened and treated for other potential infections, such as tuberculosis, and provided with counseling and support for substance use cessation.",
    "true_answer": "The most appropriate pharmacotherapy for this patient is erythromycin."
  },
  {
    "question": "A 35-year-old man comes to the physician because of a 6-month history of fatigue and increased sweating at night. He says that he feels 'constantly tired' and needs more rest than usual although he sleeps well. In the morning, his sheets are often wet and his skin is clammy. He has not had any sore throat, runny nose, or cough recently. He has not traveled anywhere. Over the past 4 months, he has had a 6.8-kg (15-lb) weight loss, despite having a normal appetite. He does not drink or urinate more than usual. He is 181 cm (5 ft 11 in) tall and weighs 72 kg (159 lb); BMI is 22 kg/m2. His temperature is 37.9\u00b0C (100.2\u00b0F), pulse is 65/min, and blood pressure is 120/70 mm Hg. Physical examination shows no abnormalities. An HIV screening test and confirmatory test are both positive. The CD4 count is 600 cells/\u03bcl and the viral load is 104 copies/mL. Treatment with lamivudine, zidovudine, and indinavir is begun. The patient is at greatest risk for what adverse effects?",
    "answer": "The patient is at greatest risk for adverse effects related to the antiretroviral therapy (ART) medications, specifically:\n\n1. **Lactic acidosis and hepatotoxicity** with lamivudine and zidovudine (nucleoside reverse transcriptase inhibitors, NRTIs): These medications can cause mitochondrial toxicity, leading to lactic acidosis and hepatotoxicity.\n2. **Nephrolithiasis (kidney stones)** with indinavir (protease inhibitor, PI): Indinavir can crystallize in the urine, leading to kidney stones.\n3. **Hyperlipidemia and insulin resistance** with indinavir (PI): Protease inhibitors, including indinavir, can cause metabolic abnormalities, such as hyperlipidemia and insulin resistance, which increase the risk of cardiovascular disease.\n4. **Gastrointestinal intolerance** with all three medications: The patient may experience nausea, vomiting, diarrhea, or abdominal pain due to the medications.\n5. **Bone marrow suppression** with zidovudine: Zidovudine can cause bone marrow suppression, leading to anemia, neutropenia, or thrombocytopenia.\n\nHowever, considering the specific combination of medications and the patient's overall health, the most significant risk is likely related to the **mitochondrial toxicity** associated with lamivudine and zidovudine, which can lead to **lactic acidosis and hepatotoxicity**.\n\nIt's essential to monitor the patient's laboratory results, including liver function tests, lactate levels, and complete blood counts, to quickly identify and manage any potential adverse effects.",
    "true_answer": "The patient is at greatest risk for developing urolithiasis as an adverse effect."
  },
  {
    "question": "A 52-year-old man is brought to the emergency department because of headaches, vertigo, and changes to his personality for the past few weeks. He was diagnosed with HIV 14 years ago and was started on antiretroviral therapy at that time. Medical records from one month ago indicate that he followed his medication schedule inconsistently. Since then, he has been regularly taking his antiretroviral medications and trimethoprim-sulfamethoxazole. His vital signs are within normal limits. Neurological examination shows ataxia and apathy. Mini-Mental State Examination score is 15/30. Laboratory studies show: Hemoglobin 12.5 g/dL Leukocyte count 8400/mm3 Segmented neutrophils 80% Eosinophils 1% Lymphocytes 17% Monocytes 2% CD4+ T-lymphocytes 90/\u03bcL Platelet count 328,000/mm3 An MRI of the brain with contrast shows a solitary ring-enhancing lesion involving the corpus callosum and measuring 4.5 cm in diameter. A lumbar puncture with subsequent cerebrospinal fluid analysis shows slight pleocytosis, and PCR is positive for Epstein-Barr virus DNA. What is the most likely diagnosis?",
    "answer": "Based on the patient's symptoms, laboratory results, and imaging studies, the most likely diagnosis is Primary Central Nervous System Lymphoma (PCNSL).\n\nHere's why:\n\n1. **Immunocompromised status**: The patient has a history of HIV infection and a low CD4+ T-lymphocyte count (90/\u03bcL), which increases his risk for opportunistic infections and malignancies, including PCNSL.\n2. **Neurological symptoms**: The patient presents with headaches, vertigo, changes in personality, ataxia, and apathy, which are consistent with a brain tumor or mass lesion.\n3. ** Imaging findings**: The MRI shows a solitary ring-enhancing lesion involving the corpus callosum, which is a characteristic feature of PCNSL.\n4. **Cerebrospinal fluid analysis**: The presence of slight pleocytosis (increased cell count) and Epstein-Barr virus (EBV) DNA by PCR in the cerebrospinal fluid supports the diagnosis of PCNSL. EBV is a known risk factor for PCNSL in immunocompromised individuals.\n5. **Exclusion of other diagnoses**: The patient's symptoms and laboratory results do not strongly suggest other diagnoses, such as toxoplasmosis or cryptococcal meningitis, which are also common in HIV-infected individuals.\n\nPrimary Central Nervous System Lymphoma is a rare and aggressive non-Hodgkin lymphoma that arises in the brain, spinal cord, or eyes. It is more common in immunocompromised individuals, such as those with HIV/AIDS. The presence of EBV DNA in the cerebrospinal fluid is a strong indicator of PCNSL in this patient population.\n\nIt's worth noting that a definitive diagnosis of PCNSL typically requires a biopsy or histopathological examination of the tumor tissue. However, based on the clinical presentation, imaging findings, and cerebrospinal fluid analysis, PCNSL is the most likely diagnosis in this case.",
    "true_answer": "The most likely diagnosis is CNS lymphoma."
  },
  {
    "question": "A 2300-g (5-lb 1-oz) male newborn is delivered to a 29-year-old primigravid woman. The mother has HIV and received triple antiretroviral therapy during pregnancy. Her HIV viral load was 678 copies/mL 1 week prior to delivery. Labor was uncomplicated. Apgar scores are 7 and 8 at 1 and 5 minutes respectively. Physical examination of the newborn shows no abnormalities. What is the most appropriate next step in management of this infant?",
    "answer": "The most appropriate next step in the management of this infant, born to an HIV-positive mother, is to initiate antiretroviral prophylaxis to prevent mother-to-child transmission (MTCT) of HIV. This is a critical step, even though the mother was on triple antiretroviral therapy during pregnancy, because the viral load was detectable (678 copies/mL) close to the time of delivery.\n\nFor an infant born to an HIV-positive mother, the U.S. Centers for Disease Control and Prevention (CDC) and the American Academy of Pediatrics (AAP) recommend the following:\n\n1. **Administer Antiretroviral Prophylaxis:** The preferred regimen for infants born to HIV-positive mothers typically includes zidovudine (AZT) monotherapy for 4-6 weeks, starting as soon as possible after birth, ideally within the first 6-12 hours of life. However, for infants born to mothers with a viral load >1000 copies/mL near the time of delivery, or in cases where the maternal viral load is unknown, a three-drug regimen may be recommended for the newborn.\n\n2. **HIV Testing:** The infant should undergo HIV testing, typically with HIV DNA or RNA assays (such as PCR - Polymerase Chain Reaction), at birth (or as soon as possible), at 14-21 days, at 1-2 months, and at 4-6 months of age. A diagnosis of HIV infection can be made with two positive HIV DNA or RNA tests.\n\n3. **PCP Prophylaxis:** Trimethoprim/sulfamethoxazole is recommended for PCP (Pneumocystis jirovecii pneumonia) prophylaxis, starting at 4-6 weeks of age, and continuing until HIV infection is ruled out or the child is confirmed to be HIV-positive, in which case prophylaxis should continue as clinically indicated.\n\n4. **Follow-Up Care:** Regular follow-up with a pediatrician experienced in HIV care is crucial. This includes monitoring for signs of HIV infection, managing any potential side effects of antiretroviral therapy, and adjusting the treatment plan as needed based on the results of HIV testing.\n\nIn summary, the most appropriate next step in the management of this infant is to initiate antiretroviral prophylaxis (likely zidovudine, but possibly a three-drug regimen given the mother's viral load), arrange for HIV testing, and plan for follow-up care with a pediatric HIV specialist. Given the specifics of this case, consultation with a pediatric infectious disease specialist or a clinician experienced in the care of HIV-exposed infants would be beneficial to tailor the management plan to the infant's needs.",
    "true_answer": "The next best step in management for this infant is to administer zidovudine."
  }
]